Roundhill GLP-1 & Weight Loss ETF (OZEM) Dividend History

Company News

• Best ETF Areas of Last Week

  Wall Street was upbeat last week.

  Zacks Investment Research

  Featured Companies: AAPL DAPP LLY LRNZ NVDA SMH UNG UNL WGMI
• ETFs Bet High On Weight Loss Drugs, But Industry Observers Question Long-Term Potential

  With more than 10% of the global population now suffering from obesity, the share prices of companies providing the latest weight-loss drugs have surged. However, according to industry observers, investors considering exposure through the newly launched weight-loss exchange-traded funds (ETFs) need to evaluate their potential. The Roundhill GLP-1 Weight Loss ETF (NASDAQ:OZEM) and the Amplify Weight Loss Drug and Treatment ETF (NYSE:THNR) debuted on May 21 with an expense ratio of 0.59%. Both ETFs have significant weightings in industry giants Eli Lilly And Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO), with OZEM and THNR allocating about 40% and 30%, respectively, to these companies. Eli Lilly and ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: LLY THNR
• ETFs to Profit from the Weight Loss Drug Boom

  The market for GLP-1 drugs could soar to $130 billion by 2030

  Zacks Investment Research

  Featured Companies: HRTS LLY NVDA THNR TSLA
• New Weight Loss ETF Is Essentially A Play On Eli Lilly, Novo Nordisk

  The recently launched Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) is gaining traction among investors, primarily due to its significant holdings in pharmaceutical giants Eli Lilly and Co (NYSE:LLY) and Novo Nordisk A/S (NYSE:NVO). These two companies are at the forefront of the burgeoning weight-loss drug market, making up over 40% of OZEM’s portfolio. This ETF presents a unique opportunity for investors to gain exposure to the weight-loss sector through these dominant players. We covered the ETF’s launch here: EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic Weight-Loss Drug ETFs: A Targeted Investment Weight-loss drug ETFs like OZEM are designed to capitalize on the growing demand for effective weight-management solutions, driven by the increasing prevalence of obesity. The focal point of these ETFs is GLP-1 drugs, a class of medications known for their dual benefits in treating type 2 diabetes ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: LLY
• EXCLUSIVE: Roundhill Investments Launches Weight Loss ETF For Exposure To Blockbuster Drugs Like Ozempic

  Roundhill Investments launched a new exchange-traded fund (ETF) Tuesday. What Happened: The Roundhill GLP-1 & Weight Loss ETF (NASDAQ:OZEM) marks a significant milestone as the world's first GLP-1 ETF. Roundhill asserts that weight loss drugs, particularly GLP-1 agonists, are among the most revolutionary advancements in the global pharmaceuticals industry. Notably, OZEM is the only ETF providing dedicated exposure to transformative weight loss stocks such as Eli Lilly & Co. (NYSE:LLY), the producer of Zepbound, and Novo Nordisk A/S (NYSE:NVO), the maker of Ozempic. “These new treatments work incredibly well,” Roundhill CEO Dave Mazza told Benzinga. Citing Goldman Sachs research, Mazza believes the market for weight loss drugs could expand more than 16 times its current size from its current $6 billion and reach $100 billion by 2030. Mazza compared the market dominance of Novo Nordisk and Eli Lilly in the weight loss drug sector to Nvidia Corp.‘s (NASDAQ:NVDA) position in generative AI. Over 40% of the OZEM portfolio is invested in these two weight-loss drug ...Full story available on Benzinga.com

  Benzinga

  Featured Companies: AMGN CHAT HIMS LLY NVDA VKTX